You searched for "diagnosis"

562 results found

Beware of the ambiguous testicular lump

In busy day-to-day practice, we are often faced with puzzling situations. A useful mnemonic is 4-T: torsion, trauma, tumour and tuberculosis (infections). This case review in the BMJ is about a 34-year-old man presenting to A&E with left testicular pain...

RSM: Andrology update 2026: advances across benign and oncological practice

Join the Royal Society of Medicine (RSM) Urology Section, in collaboration with the British Association of Urological Surgeons (BAUS) Section of Andrology and the British Society of Sexual Medicine, for this one-day meeting exploring the latest developments in andrology, penile cancer and testicular cancer. Returning for its biannual meeting, the programme brings together leading surgeons, physicians, psychologists and specialist nurses, and will examine advances in clinical practice across benign andrology, penile cancer and testicular cancer.

What’s new in post prostatectomy incontinence?

With an ageing population, the number of men being diagnosed with prostate cancer each year is steadily rising. With more specific investigations, such as multiparametric magnetic resonance imaging (MpMRI) and transperineal biopsies, the number of cases diagnosed at an earlier...

Andrology (2020)

Case 1 What is the diagnosis based on the blood test, and how is the diagnosis made? What additional blood tests are required? What are the clinical manifestations of this? What are the options / modes of delivery for treatment?...

Sexually transmitted infections

Case 1 A 27-year-old man presents to the clinic with multiple asymptomatic penile lesions. 1. What is the diagnosis? 2. What are the likely pathogens which cause these lesions? 3. What treatment options are available to treat these lesions? 4....

Improving on the Rotterdam Prostate Cancer Risk Calculator

Following the PROMIS trial [1], many cancer centres in the UK are now offering pre-biopsy multiparametric MRI (mpMRI) for men suitable for radical treatment. The European Association of Urology for Prostate Cancer (PCa) guidelines recommend individual risk stratification before the...

Does empowering men on active surveillance for prostate cancer improve patient compliance and reduce conversion to treatment?

Active surveillance is a major treatment option for patients with favourable prognosis prostate cancer, such as those regarded as Cambridge Prognostic Group (CPG) 1 and 2 [1]. The rationale for this management strategy is the lack of survival benefit from...

An account of training and practice of urology in Nigeria

Nigeria is the most populous nation on the continent of Africa. Within the country, there are 33,303 general hospitals and 59 tertiary hospitals to serve a population of approximately 210 million people [1]. Specialty-based practice of urology is domiciled in...

COVID-19: the impact on urology so far

“How very little can be done under the spirit of fear.” Florence Nightingale Since 31 December 2019 when a cluster of pneumonia cases with an unknown cause were first referred to the WHO Country Office in China, there has been...

Imaging and Intervention in Urinary Tract Infections and Urosepsis

Urinary tract infections (UTIs) are highly prevalent in the community and account for approximately 40% of hospital-acquired infections. Yet, they are often underestimated and under-diagnosed: as one chapter of this book is entitled, nothing is simple about acute pyelonephritis. This...

Abiraterone acetate in men with castration-resistant prostate cancer

With emerging results from the Stampede and Latitude studies, abiraterone has taken the forefront in the management of metastatic prostate cancer while researchers try to identify the ideal timing for administration. It is a potent inhibitor of CYP17 which results...

Radium-223 treatment outcomes after multiple lines of mCRPC therapy in clinical practice: implication of pre-treatment spinal epidural disease

There are a number of treatments now available to patients with metastatic castrate-resistant prostate cancer (mCRPC). However, the optimal timing and order in which they are given is less clear. Radium-223 was FDA-approved for mCRPC patients with symptomatic bone metastases...